Lantern Pharma (NASDAQ: LTRN) has reported a significant milestone in its ongoing Phase 1 trial of LP-284, a next-generation acylfulvene, with the observation of a complete metabolic response in a heavily pretreated patient with aggressive Grade 3 non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL). This marks the first such response for LP-284, highlighting its potential as a groundbreaking therapy for refractory lymphomas.
The patient, who had previously failed three treatment regimens including CAR-T and bispecific antibody therapy, responded after just two cycles of LP-284. Developed using Lantern’s RADR(R) AI platform, LP-284's synthetic lethal mechanism could represent a paradigm shift in the treatment of aggressive lymphomas, supporting accelerated development in the $4 billion global B-cell cancer market.
This development is crucial as it opens new avenues for patients with limited treatment options, showcasing the power of AI in oncology drug development. Lantern Pharma's approach, leveraging over 200 billion oncology-focused data points, has the potential to significantly reduce the cost and time of bringing new therapies to market, with an average of 2-3 years from initial AI insights to first-in-human clinical trials.
